CervoMed Stock Slides Into Long Weekend as CRVO’s Cash Clock Tests Phase 3 Hopes
CervoMed Inc. shares fell 11% this week, closing at $3.06 Friday after a first-quarter update highlighted funding needs for its planned Phase 3 dementia trial. The company reported $12.9 million in cash as of March 31, with a runway into September 2026. No grant revenue was recorded in Q1, and net loss widened to $8 million. Nasdaq is closed Monday for Memorial Day; trading resumes Tuesday.